Can Fite BiopharmaCANF -1.97%55 Median PS Value is $8.56 as of Jun. 25, 2026, which is 287% above its 10-year median of 2.21. GuruFocus rates CANF with a GF Score™ of 55/100 and a GF Value™ of $5.98 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 277 Biotechnology companies, Can Fite Biopharma ranks better than 75.09% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Can Fite Biopharma's Median PS Value or its related term are showing as below:
CANF'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35 Med: 2.21 Max: 2.21
Current: 0.35
During the past 13 years, the highest Price to Median PS Value of Can Fite Biopharma was 2.21. The lowest was 0.35. And the median was 2.21.
CANF's Price-to-Median-PS-Value is ranked better than 75.09% of 277
companies
in the Biotechnology industry
Industry Median: 0.63
vs CANF: 0.35
Can Fite Biopharma (AMEX:CANF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Can Fite Biopharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.99
/
8.56
=
0.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma Median PS Value Related Terms
Can Fite Biopharma Median PS Value Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CANF vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Can Fite Biopharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 16.5891.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Can Fite Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.516.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (CANF) has a Median PS Value of $8.56 as of Jun. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Can Fite Biopharma and its competitors. This is 287% above median its historical median of 2.21. Over the past decade, Can Fite Biopharma's Median PS Value has ranged from 0.35 to 2.21. According to the industry distribution chart, Can Fite Biopharma ranks #69 out of 277 companies in the Biotechnology industry, placing it in the top 24.9%.
Is Can Fite Biopharma's Median PS Value too high?
Can Fite Biopharma's current Median PS Value of $8.56 is 287% above median its 10-year median of 2.21. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 2.21. The Biotechnology industry median Median PS Value is 0.63. Can Fite Biopharma's value of $8.56 is 1258.7% above this industry median. Based on the distribution chart, Can Fite Biopharma ranks #69 out of 277 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #69 out of 277 companies for Median PS Value. This places Can Fite Biopharma in the top 25% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.63. Can Fite Biopharma's value of $8.56 is 1258.7% above this benchmark. Historically, Can Fite Biopharma's own Median PS Value has ranged from 0.35 to 2.21 over the past decade. While the company's 10-year median is 2.21 vs. the industry median of 0.63, Can Fite Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current Median PS Value of $8.56 is 1258.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Can Fite Biopharma and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current Median PS Value is $8.56, which is 287% above median its own 10-year median of 2.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.98, compared to a current price of $2.99 — trading 50% below its estimated fair value. The current Median PS Value is $8.56, which is 287% above median its 10-year median of 2.21 and 1258.7% above the Biotechnology industry median of 0.63. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Median PS Value is $8.56 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $2.99 is trading 50% below its estimated GF Value™ of $5.98.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
Median PS Value: $8.56 (287% above median its 10-year median of 2.21)
GF Value™: $5.98 vs. price of $2.99 (50% below fair value)
Industry Position: 1258.7% above the Biotechnology median (#69 of 277)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score
Get the complete analysis for CANF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
